Use of negatively reinforcing electrical brain stimulation to detect conventional and nonconventional anxiolytics as well as an anxiogenic drug

Pharmacology Biochemistry and Behavior

Volumn 68, Issue 1, 2001, Pages 33-42

  Jung, M E ^a   Depoortere, R ^a   Oglesby, M W ^a  

^a UNIVERSITY OF NORTH TEXAS   (United States)

Author keywords

Anxiogenic; Anxiolytic; Buspirone; Diazepam; Flumazenil; Negative reinforcement; Pentylenetetrazole; Switch off response

Indexed keywords

ABECARNIL; BENZODIAZEPINE; BENZODIAZEPINE RECEPTOR; BUSPIRONE; DIAZEPAM; FLUMAZENIL; PENTETRAZOLE; SEROTONIN 1A RECEPTOR; ANTI ANXIETY AGENTS, BENZODIAZEPINE; ANXIOLYTIC AGENT; BENZODIAZEPINE RECEPTOR AFFECTING AGENT; CARBOLINE DERIVATIVE; CONVULSANT AGENT;

ANIMAL EXPERIMENT; ARTICLE; BRAIN DEPTH STIMULATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG INHIBITION; DRUG POTENTIATION; DRUG USE; FREQUENCY MODULATION; LATENT PERIOD; MALE; NONHUMAN; PERIAQUEDUCTAL GRAY MATTER; PRIORITY JOURNAL; RAT; ANIMAL; ANXIETY; BRAIN; ELECTRODE; ELECTROSTIMULATION; IATROGENIC DISEASE; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; RAT STRAIN; REINFORCEMENT;

ANIMAL; ANTI-ANXIETY AGENTS; ANTI-ANXIETY AGENTS, BENZODIAZEPINE; ANXIETY; BRAIN; BUSPIRONE; CARBOLINES; CONVULSANTS; DIAZEPAM; ELECTRIC STIMULATION; ELECTRODES; FLUMAZENIL; GABA MODULATORS; MALE; PENTYLENETETRAZOLE; RATS; RATS, LONG-EVANS; REINFORCEMENT (PSYCHOLOGY); SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0035077873     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(00)00435-4     Document Type: Article

References (51)

1. Benzodiazepine receptors in the periaqueductal gray mediate antiaversive drug action
2. Abecarnil, a new beta-carboline, in the treatment of anxiety
3. The first double-blind, placebo-controlled trial of a partial benzodiazepine agonist abecarnil (ZK 112-119) in generalized anxiety disorder
4. Enhancing GABAergic transmission reverses the aversive state in rats induced by electrical stimulation of the periaqueductal grey region
5. GABA mediation of the anti-aversive action of minor tranquilizers
6. The fractional reduction in noxious stimulation required to produce "just noticeable" learning
7. Ethological evaluation of the effects of acute and chronic buspirone treatment in the murine elevated plus-maze test: Comparison with haloperidol
8. On the elevated plus-maze the anxiolytic-like effects of the 5-HT(1A) agonist, 8-OH-DPAT, but not the anxiogenic-like effects of the 5-HT(1A) partial agonist, buspirone, are blocked by the 5-HT1A antagonist, WAY 100635
9. β-carbolines enhance shock-induced suppression of drinking in rats
10. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder
11. Learning motivated by electrical stimulation of the brain
12. Differential pharmacological reactivity of aversion induced by stimulation of periaqueductal gray or mesencephalic locomotor region
13. Aversion induced by electrical stimulation of the mesencephalic locomotor region in the intact and freely moving rat
14. Flight induced by infusion of bicuculline into periventricular structures
15. Severe anxiety induced by FG 7142, a β-carboline ligand for benzodiazepine receptors
16. Effect of acute and chronic administration of buspirone on serotonin and benzodiazepine receptor subtypes in the rat brain: An autoradiographic study
17. Effects of anxiolytic drugs on escape behavior induced by dorsal central gray stimulation in rats
18. Characterization of the behavioral profile of the non-peptide CRF receptor antagonist CP-154, 526 in anxiety models in rodents. Comparison with diazepam and buspirone
19. Comparison of the pharmacological properties of classical and novel BZ-receptor ligands
20. Selective antagonists of benzodiazepines
21. Comparison of buspirone and diazepam in generalized anxiety disorder
22. A multicentre double-blind comparison of hydroxyzine, buspirone and placebo in patients with generalized anxiety disorder
23. Behavioral analogues of anxiety. Animal models
24. Reversal of the antiaversive and anticonvulsant actions of diazepam, but not of progabide, by a selective antagonist of benzodiazepine receptors
25. A double-blind evaluation of the safety and efficacy of abecarnil, alprazolam, and placebo in outpatients with generalized anxiety disorder
26. Neurochemical effects of buspirone in rat hippocampus. Evidence for selective activation of 5-HT neurons
27. Abecarnil and alprazolam in humans: Behavioral, subjective and reinforcing effects
28. A receptor complex ligands in two models of anxiety
29. Approach-escape interactions in rat brain
30. Characterization of rat exploratory behavior using the exploration box test
31. Treatment of generalized anxiety disorder: Preliminary clinical experience with buspirone
32. Abecarnil for the treatment of generalized anxiety disorder: A placebo-controlled comparison of two dosage range of abecarnil and buspirone
33. Does buspirone have anxiogenic properties?
34. Effect of diazepam on cortical 5-HT release and behaviour in the guinea-pig on exposure to the elevated plus maze
35. "Anxiolytic" action of diazepam and abecarnil in a modified open field test
36. Buspirone and diazepam in anxiety: A controlled study
37. Metrazol in a "normal" volunteer population
38. Mapping of jumping, rearing, squealing and switch-off behaviors elicited by periaqueductal gray stimulation in the rat
39. Fear and anxiety induced by benzodiazepine receptor inverse agonists
40. Role of the periaqueductal gray substance in the antianxiety action of benzodiazepines
41. Multiple GABA receptors and associated regulatory sites
42. Parallel processing strategies in the application of microcomputers to the behavioral laboratory
43. Meta-analysis of the safety and tolerability of two dose regimens of buspirone in patients with persistent anxiety
44. Abecarnil, a metabolically stable, anxioselective beta-carboline acting at benzodiazepine receptors
45. Modulation of anxiety by beta-carbolines and other benzodiazepine receptor ligands: Relationship of pharmacological to biochemical measures of efficacy
46. What are the differences between abecarnil and conventional benzodiazepine anxiolytics?
47. Mesencephalically induced escape behavior and avoidance performance
48. Behavioral and biochemical characterization of benzodiazepine receptor partial agonists in pigeons
49. Anticonflict effects of acute and chronic treatments with buspirone and gepirone in rats